Treating Expecting Mothers With Sotrovimab for COVID-19
Late breaking data was reported utilizing the monoclonal antibody during the era of when Omicron variant was the predominant strain and demonstrated good outcomes and tolerability.
Pregnancy and a COVID-19 diagnosis can be especially problematic for both the mother and baby. Progression to severe disease can complicate a pregnancy and, in some cases, lead to hospitalization.
In the larger population, patients have had a greater exposure to monoclonal antibodies. However, pregnant women have seen limited treatment using this therapy class, and therefore have had limited studies and data.
A new small study presented at IDWeek 2022 looked at using a monoclonal antibody for pregnant women. Jessica Tuan, MD, MS, infectious diseases instructor, Yale University School of Medicine, presented data in this late breaking abstract, “Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO).”
Investigators performed a review of electronic medical records of 22 pregnant COVID-19 patients treated with sotrovimab within one health system in New England.
“We assessed demographics, medical history, and Monoclonal Antibody Screening Score (MASS),” the investigators wrote. “Clinical outcomes assessed included emergency department (ED) visit < 24 hours, hospitalization, ICU admission, and/or death within 29 days of sotrovimab.”
Tuan spoke to Contagion during the conference and her team of investigators reported both mothers and babies did well on the treatment. “We looked at the outcomes and we saw that the women generally did well, as well as the neonates,” Tuan said.
In speaking with Contagion, Tuan provided some more insights about the study, discussed the tolerability of sotrovimab, and their aspirations for future studies to seek out more data to help understand the profile of these medications on this patient population.
